JP-2025514858-A5 -

Dates

Publication Date

20260507

Application Date

20230428

Description

Some aspects are included in the claims. For example, this disclosure provides the following embodiments. [Section 1] A first antibody or antigen-binding fragment thereof that specifically binds to the spike protein of SARS-CoV-2, wherein the first antibody or antigen-binding fragment comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 of SEQ ID NOs. 31, 32, 37, 34, 35, and 36, respectively, A second antibody or antigen-binding fragment thereof that specifically binds to the spike protein of SARS-CoV-2, wherein the second antibody or antigen-binding fragment comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 of SEQ ID NOs. 69, 70, 71, 73, 74, and 75, respectively, A composition or combination containing the following: [Section 2] A first antibody or antigen-binding fragment thereof that specifically binds to the spike protein of SARS-CoV-2, wherein the first antibody or antigen-binding fragment competitively inhibits the binding of an antibody comprising a variable heavy chain (VH) containing the amino acid sequence of SEQ ID NO: 63 and a variable light chain (VL) containing the amino acid sequence of SEQ ID NO: 61 to the spike protein of SARS-CoV-2, A second antibody or antigen-binding fragment thereof that specifically binds to the spike protein of SARS-CoV-2, wherein the second antibody or antigen-binding fragment competitively inhibits the binding of an antibody comprising a variable heavy chain (VH) containing the amino acid sequence of SEQ ID NO: 68 and a variable light chain (VL) containing the amino acid sequence of SEQ ID NO: 72 to the spike protein of SARS-CoV-2, A composition or combination containing the following: [Section 3] A first antibody or antigen-binding fragment thereof that specifically binds to the spike protein of SARS-CoV-2, wherein the first antibody or antigen-binding fragment binds to the same SARS-CoV-2 spike protein epitope as an antibody comprising a variable heavy chain (VH) containing the amino acid sequence of SEQ ID NO: 63 and a variable light chain (VL) containing the amino acid sequence of SEQ ID NO: 61, A second antibody or antigen-binding fragment thereof that specifically binds to the spike protein of SARS-CoV-2, wherein the second antibody or antigen-binding fragment binds to the same SARS-CoV-2 spike protein epitope as an antibody comprising a variable heavy chain (VH) containing the amino acid sequence of SEQ ID NO: 68 and a variable light chain (VL) containing the amino acid sequence of SEQ ID NO: 72, A composition or combination containing the following: [Section 4] The composition or combination according to claim 2 or 3, wherein the first antibody or its antigen-binding fragment comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 of SEQ ID NOs. 31, 32, 37, 34, 35, and 36, respectively. [Section 5] The composition or combination according to claim 4, wherein the first antibody or its antigen-binding fragment comprises VH containing the amino acid sequence of SEQ ID NO: 63 and VL containing the amino acid sequence of SEQ ID NO: 61. [Section 6] The composition or combination according to any one of claims 2 to 5, wherein the second antibody or its antigen-binding fragment comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 of Sequence ID Nos. 69, 70, 71, 73, 74, and 74, respectively. [Section 7] The composition or combination according to claim 6, wherein the second antibody or its antigen-binding fragment comprises a VH containing the amino acid sequence of SEQ ID NO: 68 and a VL containing the amino acid sequence of SEQ ID NO: 72, and optionally the second antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 76 and a light chain containing the amino acid sequence of SEQ ID NO: 77. [Section 8] The composition or combination according to any one of claims 1 to 7, wherein the first antibody or its antigen-binding fragment comprises VH containing the amino acid sequence of SEQ ID NO: 63 and/or VL containing the amino acid sequence of SEQ ID NO: 61. [Section 9] The composition or combination according to any one of claims 1 to 8, wherein the second antibody or its antigen-binding fragment comprises a VH containing the amino acid sequence of SEQ ID NO: 68 and/or a VL containing the amino acid sequence of SEQ ID NO: 72, and optionally the second antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 76 and a light chain containing the amino acid sequence of SEQ ID NO: 77. [Section 10] The composition or combination according to any one of claims 1 to 9, wherein the composition or combination neutralizes the SARS-CoV-2 virus, and optionally neutralizes SARS-CoV-2 BA. 2.12.1 with an IC50 of 25 ng/mL or less or an IC50 of 20 ng/mL or less. [Section 11] The composition or combination according to any one of claims 26 to 38, wherein the composition or combination neutralizes SARS-CoV-2 D614G, SARS-CoV-2 Alpha, SARS-CoV-2 Delta + T51I + T95I, SARS-CoV-2 BA. 1,